Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

Abstract

A public anti-COVID antibody repertoire Most analyses of the antibody responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have focused on antibodies cloned from memory B cells. This approach has led researchers to conclude that neutralizing antibodies (nAbs) primarily target the receptor-binding domain (RBD) of the virus's spike protein. Voss et al. took a different approach, using proteomic deconvolution of the serum immunoglobulin G antibody repertoire from four COVID-19 convalescent patients. They found that the nAb response was largely directed against epitopes such as the N-terminal domain (NTD), which lie outside the RBD. Several of these nAbs were shared among donors and targeted an NTD epitope that is frequently mutated by variants of concern. Science , abg5268, this issue p. 1108

Cited by papers we hold 12

• Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? · 2022
  Not checked
• An Immunoproteomic Survey of the Antibody Landscape: Insights and Opportunities Revealed by Serological Repertoire Profiling · 2022
  Not checked
• A Molecular Analysis of Memory B Cell and Antibody Responses Against Plasmodium falciparum Merozoite Surface Protein 1 in Children and Adults From Uganda · 2022
  Not checked
• Structural biology of SARS-CoV-2: open the door for novel therapies · 2022
  No notice
• Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
  No notice
• A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants · 2021
  Not checked
• Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants · 2021
  No notice
• Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects · 2021
  No notice
• Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies · 2021
  No notice
• Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape · 2021
  No notice
• Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants · 2021
  No notice
• Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.